
NYSEHealthcareDrug Manufacturers - Specialty & Generic
最新資料
US$14.89
+US$0.06 · +0.40%
Established in 1984 and headquartered in Hyderabad, India, Dr. Reddy's Laboratories Limited functions as a fully integrated global pharmaceutical entity. Its business is structured into several core divisions. The Global Generics segment is responsible for the production and distribution of prescription and over-the-counter finished pharmaceutical products, marketed either under their own brand names or as generic versions therapeutically equivalent to branded formulations, also encompassing biologics. The Pharmaceutical Services and Active Ingredients (PSAI) division manufactures and supplies active pharmaceutical ingredients (APIs) and intermediates, which are fundamental components for finished drugs, alongside offering contract research services and custom production of APIs and steroids. The Proprietary Products segment is dedicated to the research and development of unique and differentiated drug formulations. Furthermore, its "Others" segment focuses on developing treatments for oncology and inflammatory conditions. The company's therapeutic reach spans numerous areas including gastro-intestinal, cardiovascular, anti-diabetic, dermatological, oncology, respiratory, stomatological, urological, and nephrological health. Dr. Reddy's also maintains a strategic collaboration with Curis, Inc., centered on the discovery, development, and commercialization of small molecule antagonists for immuno-oncology and precision oncology applications.
前收盤價
US$14.89
+US$0.06 · +0.40%
盤中時間採用ET。市場資料可能有所延遲。
Established in 1984 and headquartered in Hyderabad, India, Dr. Reddy's Laboratories Limited functions as a fully integrated global pharmaceutical entity. Its business is structured into several core divisions. The Global Generics segment is responsible for the production and distribution of prescription and over-the-counter finished pharmaceutical products, marketed either under their own brand names or as generic versions therapeutically equivalent to branded formulations, also encompassing biologics. The Pharmaceutical Services and Active Ingredients (PSAI) division manufactures and supplies active pharmaceutical ingredients (APIs) and intermediates, which are fundamental components for finished drugs, alongside offering contract research services and custom production of APIs and steroids. The Proprietary Products segment is dedicated to the research and development of unique and differentiated drug formulations. Furthermore, its "Others" segment focuses on developing treatments for oncology and inflammatory conditions. The company's therapeutic reach spans numerous areas including gastro-intestinal, cardiovascular, anti-diabetic, dermatological, oncology, respiratory, stomatological, urological, and nephrological health. Dr. Reddy's also maintains a strategic collaboration with Curis, Inc., centered on the discovery, development, and commercialization of small molecule antagonists for immuno-oncology and precision oncology applications.
日內區間
目前US$14.89
52週區間
目前US$14.89
盤中時間採用ET。市場資料可能有所延遲。
Established in 1984 and headquartered in Hyderabad, India, Dr. Reddy's Laboratories Limited functions as a fully integrated global pharmaceutical entity. Its business is structured into several core divisions. The Global Generics segment is responsible for the production and distribution of prescription and over-the-counter finished pharmaceutical products, marketed either under their own brand names or as generic versions therapeutically equivalent to branded formulations, also encompassing biologics. The Pharmaceutical Services and Active Ingredients (PSAI) division manufactures and supplies active pharmaceutical ingredients (APIs) and intermediates, which are fundamental components for finished drugs, alongside offering contract research services and custom production of APIs and steroids. The Proprietary Products segment is dedicated to the research and development of unique and differentiated drug formulations. Furthermore, its "Others" segment focuses on developing treatments for oncology and inflammatory conditions. The company's therapeutic reach spans numerous areas including gastro-intestinal, cardiovascular, anti-diabetic, dermatological, oncology, respiratory, stomatological, urological, and nephrological health. Dr. Reddy's also maintains a strategic collaboration with Curis, Inc., centered on the discovery, development, and commercialization of small molecule antagonists for immuno-oncology and precision oncology applications.
日內區間
目前US$14.89
52週區間
目前US$14.89
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目(INR) | 2026會計年度 | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 |
|---|---|---|---|---|---|
| 營收 | 3534.72億 INR | 3255.35億 INR | 2791.64億 INR | 2458.79億 INR | 2143.91億 INR |
| 銷貨成本 | 1669.53億 INR | 1351.07億 INR | 1155.57億 INR | 1065.36億 INR | 1005.51億 INR |
| 毛利 | 1865.19億 INR | 1904.28億 INR | 1636.07億 INR | 1393.43億 INR | 1138.4億 INR |
| 研究與開發 | 253.14億 INR | 273.8億 INR | 228.73億 INR | 193.81億 INR | 174.82億 INR |
| 銷售、一般及管理費用 | 1123.37億 INR | 938.7億 INR | 772.01億 INR | 680.26億 INR | 620.81億 INR |
| 營業費用 | 1376.51億 INR | 1185.85億 INR | 958.78億 INR | 821.99億 INR | 843.64億 INR |
| 利息收入 | 82.81億 INR | 26.77億 INR | 22.78億 INR | 11.8億 INR | 9.65億 INR |
| 利息支出 | 39.33億 INR | 28.29億 INR | 17.11億 INR | 14.28億 INR | 9.58億 INR |
| 折舊和攤銷 | 216.82億 INR | 170.58億 INR | 148.41億 INR | 126.36億 INR | 118.24億 INR |
| 營業利益 | 488.68億 INR | 718.43億 INR | 677.29億 INR | 571.44億 INR | 294.76億 INR |
| 淨利 | 450.87億 INR | 565.44億 INR | 556.84億 INR | 450.67億 INR | 235.68億 INR |
公司資料更新於 2026年11月22日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動,並非 GoAI 建議。
平均目標
US$14.35
下跌空間 3.63%年度分割調整後的每股現金分配。
US$0.0915
2025年(完整年度)+35.9% 自從 2021
2026年(部分年度):US$0.0834
US$0.0673
2,021
US$0.1531
2,022
US$0.1941
2,023
US$0.0808
2,024
US$0.0915
2,025
US$0.0834
2,026*
* 在現有股息歷史記錄中,該日曆年僅包含部分期間。
| 行動 | 除息日 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股息 | 2026年7月24日 | US$0.0834Annual | 2026年7月9日 | 2026年8月5日 |
股息 | 2025年7月25日 | US$0.0915Annual | 2025年7月10日 | 2025年8月6日 |
股息 | 2024年7月30日 | US$0.4762Annual | 2024年7月15日 | 2024年8月12日 |
股息 | 2023年7月28日 | US$0.4826Monthly | 2023年7月10日 | 2023年8月11日 |
股息 | 2023年7月7日 | US$0.488Annual | 2023年7月10日 | 2023年8月11日 |
股息 | 2022年8月1日 | US$0.3784Monthly | 2022年7月11日 | 2022年8月12日 |
除息 2026年7月24日
US$0.0834
Annual
2026年7月9日登記 · 支付日 2026年8月5日
除息 2025年7月25日
US$0.0915
Annual
2025年7月10日登記 · 支付日 2025年8月6日
除息 2024年7月30日
US$0.4762
Annual
2024年7月15日登記 · 支付日 2024年8月12日
除息 2023年7月28日
US$0.4826
Monthly
2023年7月10日登記 · 支付日 2023年8月11日
除息 2023年7月7日
US$0.488
Annual
2023年7月10日登記 · 支付日 2023年8月11日
除息 2022年8月1日
US$0.3784
Monthly
2022年7月11日登記 · 支付日 2022年8月12日
報告持有此股票曝險的交易所交易基金。
Alliance Bernstein - AB Emerging Markets Opportunities ETFEMOP5022.81萬2.73%18.41億 USD0.70%US$40.94-5.32%
Vanguard FTSE Emerging Markets ETFVWO2655.43萬0.02%1175億 USD0.06%US$50.62-3.87%
Avantis Emerging Markets Equity ETFAVEM2352.14萬0.09%245.59億 USD0.33%US$76.04-4.76%
State Street SPDR Portfolio Emerging Markets ETFSPEM2150.12萬0.14%154.54億 USD0.07%US$44.06-3.95%
Vanguard Total International Stock ETFVXUS1238.56萬0.00%1606億 USD0.05%US$75.38-3.27%
Dimensional - Emerging Markets Core Equity 2 ETFDFEM567.85萬0.07%81.86億 USD0.39%US$32.11-4.80%
Dimensional - Emerging Core Equity Market ETFDFAE538.13萬0.06%86.83億 USD0.29%US$31.75-4.97%
Vanguard FTSE All-World ex-US ETFVEU500萬0.01%663億 USD0.04%US$73.78-3.30%
Alliance Bernstein - AB Emerging Markets Opportunities ETFEMOP
Vanguard FTSE Emerging Markets ETFVWO
Avantis Emerging Markets Equity ETFAVEM
State Street SPDR Portfolio Emerging Markets ETFSPEM
Vanguard Total International Stock ETFVXUS
Dimensional - Emerging Markets Core Equity 2 ETFDFEM
Dimensional - Emerging Core Equity Market ETFDFAE
Vanguard FTSE All-World ex-US ETFVEUAI 生成內容及延遲市場資料僅供資訊與教育用途,不構成投資建議。